C-KZ8KEVerZom
exosomes, extracellular vesicles, regenerative medicine
repairingextracellular vesicle
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KZ8K
C-KZ8KC-KZ8Kexosomes, extracellular vesicles, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Découvrez Everzom en une minute avec ses cofondateurs Jeanne Volatron et Nicolas Rousseau ! ✅
Dans le bain. Jeanne Volatron, fille de chercheurs, a évolué dans l’univers scientifique depuis le plus jeune âge. Mentor. C’est à l’occasion d’un séminaire lors de son doctorat que le déclic à eu lieu et qu’elle a rencontré LA personne déterminante. Pour bientôt. Fondée en 2019, sa société EVerZom, qui innove dans la médecine régénérative, est en passe de lancer ses essais cliniques.
Elles se sont distinguées dans un classement ou concours & sont membres de France Biotech ! Découvrez notre série sur les Pépites Healthtech, des start-up prometteuses ! Focus sur EverZom, la Pépite Healthtech #4. Jeanne Volatron, sa présidente, nous éclaire sur l’innovation développée par EverZom : développer un procédé innovant de bioproduction d’exosomes pour des applications thérapeutiques en médecine régénérative ! #esanté #healthtech #biotech #medtech http://www.france-biotech.fr/
Vous avez envie de vous lancer dans la création d’un business dans la deeptech ou vous êtes simplement curieux·se·s ? Vous souhaitez écouter des témoignages réalistes et inspirants ? Rejoignez-nous pour une table-ronde spéciale entrepreneurEs Deeptech ! Le modèle est de plus en plus fréquent en Europe grâce à la qualité de la recherche et au nombre de chercheurs·euse·s souhaitant sauter le pas de l’entrepreneuriat. Si créer une startup est déjà compliqué, monter un projet deeptech soulève des challenges spécifiques notamment en termes de financement de la R&D et du passage d’une technologie à un produit business. Comment passer du monde scientifique à la gestion d’un business ? Quelles sont les compétences à nécessairement développer ? Avec qui s’associer ? Nous interrogerons les fondatrices de plusieurs startups deeptech à différents stades de développement du projet pour connaître les défis à soulever et les compromis à réaliser pour passer le cap et monter son business. Nous nous a
"J'avais déjà l'envie de l'entrepreneuriat mais pas de projet" Jeanne Volatron nous explique comment elle est passée de chercheure à entrepreneure en créant EVerZom avec Nicolas Rousseau. Pour ne rien rater de l'actualité des Innopreneurs, suivez-nous sur les réseaux sociaux : Twitter : https://twitter.com/LesInnopreneurs Linkedin : https://www.linkedin.com/in/les-innopreneurs-044005151/ Facebook : https://www.facebook.com/Les-Innopreneurs-549727061871338/
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … t these companies to Excel by clicking here. View More With A Free Account Submit or Claim Your Company Register for Free How to Increase your Company's exposure OR Create an Account for More Register for Free View Pricing for full Business Subscription OR More about VentureRadar VentureRadar Database VentureRadar Services VentureRadar for Companies Terms & Conditions Privacy Policy Cookie Policy Copyright ©2024 VentureRadar. All Rights Reserved. Upgr … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an account with VentureRadar Refresh (When Cookies Enabled) Return to home page Create a Free Account to Follow Companies To continue, pleas
Daily deal net: December 9, 2019 - Global Venturing Global Venturing | Daily deal net: December 9, 2019 Where Global Innovation and Capital Meet Home --> Register Login Go Corporate University Impact Full Site Corporate University Impact Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its parent company... Find Out More Daily Deal Round Up: May 25, 2021 Affirm spinoff Resolve raised $60m from investors including its pare … ity of Science and Technology (Kaust), has raised $2.6m from Kaust’s Innovation Fund and oil producer Saudi Aramco’s corporate venturing unit Wa’ed Ventures, the Saudi Gazette reported yesterday. The money will go to developing sensors that could help predict natural disasters, particularly those experienced in Saudi Arabia, while also funding upgrades to Sadeem’s existing technologies for air quality, flood and traffic monitoring. Sadeem was formed in 2016 by then-Kaust prof
EVerZom. Healthcare | Current Portfolio of Aloe Private Equity (2025) | GP Intel Skip to content GP Intel . Search a GP, fund, or company ⌘K GPs Companies Pricing MCP About Sign in Start free Home / Companies / Healthcare / EVerZom EV EVerZom Healthcare · France · Active · 1yr hold EVerZom is a healthcare company, headquartered in France. Entry 2025 Hold 1yr Status Active Est. EV – Who owns EVerZom ? EVerZom is currently owned by Aloe Private Equity through Sorbonne Venture (2022 vintage), since 2025. Across its history, EVerZom has been through 4 private equity ownership periods, detailed in … 20 · VC MOIC – More from Sorbonne Venture Other portfolio companies in the same fund. Austral DX Active Healthcare France · 2025 Biomemory Active TMT France · 2024 Polygon Active Healthcare France · 2024 More PE-backed in Healthcare Comparable healthcare deals from other GPs. 3i – Implant Innovations Inc. Active Advent International US 4ways Active ECI Partners UK A Place for Mom Active Silver Lake US Abacus Pharmaceuticals Active The Carlyle Group US Abbisko Healthcare Activ
EVerZom – Funding, Valuation, Investors, News Dashboard VC firms Startups Pricing News Newsletter About API Terms of Service | © 2019-2026 Parsers, Inc [email protected] Bonus program Sign Up - 10 credits = $1 Terms of Service | ©2024 Parsers, Inc [email protected] --> Add company Sign up Log In Edit EVerZom http://www.everzom.com/ Last activity: 14.10.2025 Active Categories: BioTech Exosomes Healthcare RegenerativeMedicine Therapeutics EverZom is a nanomedecine biotech companies developing a GMP compliant extracellular vesicle manufacturing platform based on a unique proprietary technol … ds 3 Date Series Amount Investors 14.10.2025 - $11.69M Capital Gr... 17.11.2021 Grant $2.8M - 01.12.2020 - $1.33M - Mentions in press and media 5 Date Title Description 14.10.2025 EVerZom Raises €10M in Funding EVerZom, a Strasbourg, France-based biotechnology company developing exosome-based therapies for regenerative medicine applications, raised €10M in funding. The round was led by Capital Grand Est, the European Innovation Council (EIC) Fund,... 05.03.2024 Exclusive lice
EVergel - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 EVergel Last update 08 May 2025 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Exosomes Synonyms - Target - Action - Mechanism - Therapeutic Areas Other Diseases Active Indication Perianal fistula due to Crohn's disease Inactive Indication - Originator Organization Everzom SAS Active Organization Everzom SAS Inactive Organization - License Organization Everzo … ab innovation contest and the EIC Accelerator program. EVerZom's first clinical application focuses on digestive tissue regeneration using naive exosomes derived from stem cells encapsulated in a gel called EVerGel ™. EVerGel's lead indication is the healing of complex ano-perianal fistulas induced by Crohn's disease. In addition, EVerZom has identified several other indications in its pipeline, all of which have demonstrated proof of concept in vivo. These include stenosis, … en research and industry, in the interests of societal progress. To do this, we fund and support the next generation of French researcher-entrepreneurs, helping them to achieve success and international recognition. As a member of the SATT network, Erganeo is laying the foundations for a desirable future in the Paris Region ecosystem, a breeding ground for innovation with 20,000 researchers in over 350 cutting-edge research laboratories. Since its creation, Erganeo has invest … pipeline of exosome-based biotherapies. EVerZom aims to accelerate the clinical application of this novel therapeutic approach in a wide range of indications where medical need remains critical. Its most advanced drug candidate targets digestive tissue healing. Paris, December 13, 2023 - EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, today unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform
EVerZom raises €10M for exosome-based therapies | AI Tech Supports posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … ng. The round was led by Capital Grand Est , @European Innovation Council (EIC) Fund, SORBONNE VENTURE by AUDACIA , Aloe Private Equity, Paris Business Angels, Capital Cell, and several family offices. This funding will support: 🔹 The launch of EVerGel’s first clinical trial in 2026 (for Crohn’s complex perianal fistulas) 🔹 Expansion into new indications including hepatology and dermatology 🔹 Further scaling and industrialization of its GMP-compliant exosome bioproduction … form from University of Arkansas advancing regenerative medicine. Its paintable application and strong wet-tissue adhesion set a new standard for biologics delivery and tissue repair. Proud to support technologies that bridge lab innovation with real patient impact. #TechTransfer #Innovation #Biomaterials University of Arkansas Technology Ventures 2,740 followers 8mo Edited 🚀 A breakthrough University of Arkansas innovation is transforming biologics delivery and tissue repai … y Dr. Younghye Song , this cutting-edge system: 🔑 Enables paintable or topical application without damaging sensitive therapeutics like stem cells 🔑 Provides exceptional bioadhesion to wet surfaces for both external and internal use 🔑 Offers shear-thinning, tunable biomaterials adaptable to diverse clinical needs 🔑 Delivers radiation-resistant protective layers for pre-radiotherapy applications 🔑 Supports layer-by-layer tissue engineering for complex organ regeneration � … y Dr. Younghye Song , this cutting-edge system: 🔑 Enables paintable or topical application without damaging sensitive therapeutics like stem cells 🔑 Provides exceptional bioadhesion to wet surfaces for both external and internal use 🔑 Offers shear-thinning, tunable biomaterials adaptable to diverse clinical needs 🔑 Delivers radiation-resistan
Regenerative Medicine Collaboration and Licensing Deals 2019-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscription … rameters Clear insight into how deal terms vary by technology type, therapeutic application, and partner profile Support valuation and structuring decisions with evidence Ground internal discussions in real transaction data rather than assumptions Understand how leading companies approach dealmaking Visibility into partner behaviour and recurring deal structures across a highly innovative and cross-disciplinary therapeutic landscape Full visibility into deal structure and exe … es where disclosed Fully searchable deal directory (by company, technology, and application) Direct access to SEC-filed agreements and source documents Analysis of deal trends, key transactions, and active dealmakers A trusted, evidence-based reference for regenerative medicine dealmaking Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how regenerative medicine partnerships are structured, negotia … al Children’s Hospital Rubedo Life Sciences Rune Labs Russian Direct Investment Fund Rutgers University RxCell Rznomics S.Biomedics Sana Biotechnology SanBio Sangamo Therapeutics Sanofi Santen Pharmaceutical Santhera Pharmaceuticals Sant Joan de Déu-Barcelona Children’s Hospital Sapreme Technologies Sarah Cannon Research Institute Sarepta Therapeutics Sartorius Sartorius Stedim Biotech SATT Conectus Alsace SAVSU Technologies ScaleReady Scenic Biotech SCM Pharma Scopus BioPhar … cine Wake Forest University Walking Fish Therapeutics Walloon Region Investment Fund Walter Reed Army Institute of Research Washington University in St Louis WCTE Weizmann Institute Werum IT Solutions WhiteLab Genomics Wilson Wolf WindMIL Therapeutics Wisconsin Alumni Research Foundation Wiseman Cancer Research Foundation Wistar Institute W L Gor
Politique de Protection des Données à Caractère Personnel - Everzom 🔬 Skip to main content About us Who we are Our history Exosomes Exosomes : nano-messengers in intercellular communication Naive exosomes : overcoming cell therapy limitations Engineered exosomes : overcoming delivery limitations Innovation platform Therapeutic programs Scientific Resources Partnering Politique de Protection des Données à Caractère Personnel Sommaire Définitions Quel est notre rôle en matière de traitement de données à caractère personnel ? Quelles sont les modalités de collecte de vos données à caractère … également les droits que vous détenez sur vos données à caractère personnel en application des dispositions légales et réglementaires applicables. Si vous avez des questions, commentaires ou des préoccupations concernant la présente politique, vous pouvez bien entendu nous (i.e. EVerZom) les adresser aux coordonnées qui figurent infra au paragraphe « Quels sont vos droits et comment les exercer ? ». Les traitements de données à caractère personnel qui vous sont présentés et … é. Cette catégorie de destinataires peut également inclure tout éditeur d’application, de programme informatique ou d’outil qui serait utilisé(e) dans le cadre de nos activités, ou encore tout prestataire informatique ou de maintenance des applications, programmes informatiques et/ou outils utilisés par EVerZom et dans lesquel(le)s vos données à caractère personnel pourraient être traitées ; les organismes sociaux et fiscaux habilités à recevoir, dans certaines hy
10 M€ : EVERZOM "A"CCÉLÈRE | BiotechFinances en Thursday, June 25 Home Biotech Medtech Healthtech Pharma VC Ecosystem Biomap Deals Weekly 15HBXpress SUBSCRIBE THE WEEKLY 10 M€ : EVERZOM "A"CCÉLÈRE Save October 17, 2025 Translated by artificial intelligence from the original French version. Learn more Quatre mois après avoir décroché 3M€ de Bpifrance pour industrialiser sa plateforme de bioproduction “ 100 fois plus efficace ” que les procédés classiques, ce tour A permet à EVerZom de lancer dès 2026 l’essai clinique d’EVerGel dans les fistules périanales complexes associées
At the origin of EVerZom : when physics and fluid mechanics meets medicine and biology. On one hand, the daily challenges faced by physicians. A persistent unmet medical need: complex perianal… | EVerZom LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in … us gallus domesticus. This study provides valuable insights into the biomedical application of nanomaterials for wound care and regenerative medicine. Grateful to my co-authors and mentors for their contributions. Keywords: Mn₃O₄ nanoparticles | PEG | PEI | Wound healing | Nanomedicine 3 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Dian Rowe 8mo Report this post Terahertz Terahertz (THz) waves are ranged between microwave and infrared region i … the nervous system at the organism, cellular, and molecular levels. The future application perspectives of THz technologies in neuroscience are also highlighted and proposed. https://lnkd.in/e-ZKNVFd Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Olivia Dyer 8mo Report this post I am super excited to announce that my recent research: “Ex vivo robotic measurement of the acute biomechanical impact of anterior cruciate ligament rupture in rats” ha … at the Danube – another 🇩🇪 science success story! In the 1920s, German Nobel Prize winner Otto Warburg discovered that cancer cells produce energy in a way that’s different from healthy cells – a clue that metabolism plays a key role in disease. But until now, seeing metabolism in action inside the body was impossible. NVision's technology changes that. Their device, POLARIS (pictured), boosts MRI scans with special molecules that light up how cells use energy – helping re
EVerZom Funding | FundedIQ Funded IQ Browse ▾ Industries Countries Cities States & subregions Regions Funding rounds Blog Pricing Blog Pricing Get digest Home › Industries › Biotechnology › EVerZom Biotechnology EVerZom EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles. They develop a bioproduction platform to produce extracellular vesicles at a commercial scale in a GMP compliant way for pharmaceutical companies with applications in regenerative medicine and drug delivery. Extracellular vesicles that encompass exosomes, m
Bright Outlook for Exosome-Based Therapeutics and Diagnostics Despite Numerous Hurdles - That's Nice | A Science Agency Menu Insight Thought Leadership Market Research Pricing Reports Agency Strategy Brand Creative Digital & SEO Social Media Media & PR Events Consulting M&A Advisory Company Our Services Our People Our History Our Clients Careers Industry Events Strategic Partnerships News Testimonials Contact Client Portal --> Thought Leadership Exosomes Bright Outlook for Exosome-Based Therapeutics and Diagnostics Despite Numerous Hurdles Exosomes hold real promise as alterna
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … t these companies to Excel by clicking here. View More With A Free Account Submit or Claim Your Company Register for Free How to Increase your Company's exposure OR Create an Account for More Register for Free View Pricing for full Business Subscription OR More about VentureRadar VentureRadar Database VentureRadar Services VentureRadar for Companies Terms & Conditions Privacy Policy Cookie Policy Copyright ©2024 VentureRadar. All Rights Reserved. Upgr … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an account with VentureRadar Refresh (When Cookies Enabled) Return to home page Create a Free Account to Follow Companies To continue, pleas
EVerZom: Therapeutic Ambition in Exosome Biotherapies | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Nicolas Rousseau Accueil Intervenants Programme S'INSCRIRE Site du Hub NR Nicolas Rousseau EVerZom https://everzom.com/ https://www.linkedin.com/in/nicolas-rousseau-everzom-exosomes-celltherapy/ Description COO et Cofondateur 2025 © Copyright Bpifrance Accessibilité : non conforme Données personnelles Mentions légales Gestion des cookies Chargement
Portfolio | ERGANEO Everything is accelerating. What about you? Erganeo is at your disposal. Mail your topic Our activity Submit a form Our services Other Enter other… Your message For any information concerning personal data, consult the legal notices. Jobs Contact us 01 44 23 21 50 My space Français English Menu Erganeo About us Our team Our services Entrepreneurs Researchers Portfolio Start-up Technologies Partnerships Media Jobs Contact us Passer au français Fulltext search Fabrice Paublant CEO of Orixha "Today, the chances of survival from out-of-hospital cardiac arrest are ar … the site #ArtificialIntelligence Kastafiore Kastafiore offers a data collection application generator. Visit the site #Lusterpigments Auressens The technology developed by Auressens offers an alternative to metal, precious or not, in decorative & technical applications where the appearance of the metal or its optical properties are paramount. Visit the site #Thermochimie Wastemy Production of bio-fuel by pyrolysis of plastic. Visit the site #ArtificialIntelligence Sequenc
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account October 14, 2025 09:00 ET | Source: EVERZOM EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases October 14, 2025 03:00 ET | Source: EVERZOM EVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseases EVerZom raises €10M to develop exosome-based biotherapies for inf
Jeanne Volatron Accès Replay Accueil Programme Intervenants Partenaires Inscription JV Jeanne Volatron EVerZom CEO et co-confatrice https://www.linkedin.com/in/jeanne-volatron-80b668136/ Ses interventions Toutes les sessions 22 oct. 14:30 - 15:30 Session en ligne Introduction puis session plénière "Témoignages de deeptech : du laboratoire à la conquête du monde" Toutes les sessions 2020 © Copyright Bpifrance Accessibilité : non conforme Mentions légales Gestion des cookies Chargement
Regenerative Medicine Collaboration and Licensing Deals 2019-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscription … rameters Clear insight into how deal terms vary by technology type, therapeutic application, and partner profile Support valuation and structuring decisions with evidence Ground internal discussions in real transaction data rather than assumptions Understand how leading companies approach dealmaking Visibility into partner behaviour and recurring deal structures across a highly innovative and cross-disciplinary therapeutic landscape Full visibility into deal structure and exe … es where disclosed Fully searchable deal directory (by company, technology, and application) Direct access to SEC-filed agreements and source documents Analysis of deal trends, key transactions, and active dealmakers A trusted, evidence-based reference for regenerative medicine dealmaking Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how regenerative medicine partnerships are structured, negotia … al Children’s Hospital Rubedo Life Sciences Rune Labs Russian Direct Investment Fund Rutgers University RxCell Rznomics S.Biomedics Sana Biotechnology SanBio Sangamo Therapeutics Sanofi Santen Pharmaceutical Santhera Pharmaceuticals Sant Joan de Déu-Barcelona Children’s Hospital Sapreme Technologies Sarah Cannon Research Institute Sarepta Therapeutics Sartorius Sartorius Stedim Biotech SATT Conectus Alsace SAVSU Technologies ScaleReady Scenic Biotech SCM Pharma Scopus BioPhar … cine Wake Forest University Walking Fish Therapeutics Walloon Region Investment Fund Walter Reed Army Institute of Research Washington University in St Louis WCTE Weizmann Institute Werum IT Solutions WhiteLab Genomics Wilson Wolf WindMIL Therapeutics Wisconsin Alumni Research Foundation Wiseman Cancer Research Foundation Wistar Institute W L Gor
EverZom and Summit Pharmaceuticals sign exclusive distribution agreement in Japan | ERGANEO Everything is accelerating. What about you? Erganeo is at your disposal. Mail your topic Our activity Submit a form Our services Other Enter other… Your message For any information concerning personal data, consult the legal notices. Jobs Contact us 01 44 23 21 50 My space Français English Menu Erganeo About us Our team Our services Entrepreneurs Researchers Portfolio Start-up Technologies Partnerships Media Jobs Contact us Passer au français Fulltext search NEWS #STARTUP EverZom and Summit Pharm
10 M€ : EVERZOM "A"CCÉLÈRE | BiotechFinances de Donnerstag, 25. Juni Home Biotech Medtech Healthtech Pharma VC Ökosystem Biomap Deals Weekly 15HBXpress SUBSCRIBE THE WEEKLY 10 M€ : EVERZOM "A"CCÉLÈRE Save 17. Oktober 2025 Mit künstlicher Intelligenz aus der französischen Originalversion übersetzt. Mehr erfahren Quatre mois après avoir décroché 3M€ de Bpifrance pour industrialiser sa plateforme de bioproduction “ 100 fois plus efficace ” que les procédés classiques, ce tour A permet à EVerZom de lancer dès 2026 l’essai clinique d’EVerGel dans les fistules périanales complexe
Healthcare Private Placement and M&A Transactions Review Week Ending October 19, 2025 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending Oc … ctober 15, 2025. Andera Partners, Frazier Healthcare Partners, Ascenta Capital, Fund+, EQT Life Sciences, Nextech Invest, Deep Track Capital, High-Tech Gründerfonds, Seventure Partners, Bayern Kapital, OCCIDENT and Wellington Management also participated in the round. The company is a developer of chemotherapeutic drugs designed to fight cancer and chronic diseases. Kardigan: The company raised $254 million of Series B venture funding from Sequoia Heritage, ARCH Venture Partn … e company received $250 million of development capital from Thiel Bio, Founders Fund and other investors on October 16, 2025. The company is a developer of robotically-assisted ultrasound technology for non-invasive tissue ablation and tumor destruction. VeraDermics: The company raised $150 million of Series C venture funding in a deal led by SR One Capital Management on October 16, 2025, putting the company’s pre-money valuation at $140 million. LifeSci Venture Partner … rma, Pontifax Venture Capital, Pureos Bioventures, RA Capital Management, aMoon Fund and Surveyor Capital also participated in the round. The company is a developer of an antibody-drug conjugate platform designed to address resistance and improve safety in cancer therapy through novel payload innovation. Pelage: The company raised $120 million of Series B venture funding in a deal led by GV and ARCH Venture Partners on October 15, 2025, putting the company’s pre-money v … ;s pre-money valuation at $203 million. Main Street Advisors, Visionary Venture Fund and YK Bioventures also participated in the round. The company is a developer of small molecule therapeutics targeting hair follicle stem cell metabolism for treating androgenetic alopecia and hair loss. Peptilogics: The company raised $78 million of Series B ven
Evora Biosciences – A Pioneering European Exosome Therapeutics Spin-Off Subscribe Sign in Evora Biosciences – A Pioneering European Exosome Therapeutics Spin-Off Aug 16, 2025 ∙ Paid Share Evora Biosciences is emerging as a compelling example of Europe’s push into cutting-edge biotechnology for regenerative medicine. Founded in 2020 as a spin-off of the Université de Paris and INSERM, this French startup has set its sights on a novel “off-the-shelf” therapy using exosomes – nanoscale vesicles secreted by stem cells – to heal complex internal wounds. Its lead program, EVOGEX, delivers cell-deriv
%PDF-1.7 %���� 1 0 obj >/Metadata 1778 0 R/ViewerPreferences 1779 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 20 0 R 29 0 R] /MediaBox[ 0 0 841.92 595.32] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]�r Ǒ}g�a" ��8�fW�[v8� )[%kh��� @`� ``@Q������}ؼT�-���ݰÄ0�� �ԇ��M����Q���$�q��O�!�����oޮV��C#���W�V�4�MW��?\�����j�hߞ��f��@S*���w�0V��X��/��)t�qr���r� ==��������f�� U� ^�����Ͳ�iZFi�@^�)S,�Z�hp�����iaؼ�����Eeʁ������-���}��E�� p�A�e���9�� 7gכ��uyt�y����X�G�+����0���dz�n Uί`:���[�{��eZ���T3�ͼj�� �
Regenerative Medicine Collaboration and Licensing Deals 2019-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscription … rameters Clear insight into how deal terms vary by technology type, therapeutic application, and partner profile Support valuation and structuring decisions with evidence Ground internal discussions in real transaction data rather than assumptions Understand how leading companies approach dealmaking Visibility into partner behaviour and recurring deal structures across a highly innovative and cross-disciplinary therapeutic landscape Full visibility into deal structure and exe … es where disclosed Fully searchable deal directory (by company, technology, and application) Direct access to SEC-filed agreements and source documents Analysis of deal trends, key transactions, and active dealmakers A trusted, evidence-based reference for regenerative medicine dealmaking Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how regenerative medicine partnerships are structured, negotia … al Children’s Hospital Rubedo Life Sciences Rune Labs Russian Direct Investment Fund Rutgers University RxCell Rznomics S.Biomedics Sana Biotechnology SanBio Sangamo Therapeutics Sanofi Santen Pharmaceutical Santhera Pharmaceuticals Sant Joan de Déu-Barcelona Children’s Hospital Sapreme Technologies Sarah Cannon Research Institute Sarepta Therapeutics Sartorius Sartorius Stedim Biotech SATT Conectus Alsace SAVSU Technologies ScaleReady Scenic Biotech SCM Pharma Scopus BioPhar … cine Wake Forest University Walking Fish Therapeutics Walloon Region Investment Fund Walter Reed Army Institute of Research Washington University in St Louis WCTE Weizmann Institute Werum IT Solutions WhiteLab Genomics Wilson Wolf WindMIL Therapeutics Wisconsin Alumni Research Foundation Wiseman Cancer Research Foundation Wistar Institute W L Gor
EverZom x INITS - A trusted Partnership ABOUT US ')"> CONSULTING ')"> SMO NEWS CAREER CONTACT Home Home Home > News News News <- <- <- EverZom x INITS - A trusted Partnership EverZom x INITS - A trusted Partnership EverZom x INITS - A trusted Partnership Tuesday, May 6, 2025 Tuesday, May 6, 2025 EverZom x INITS – A Trusted Partnership We’re proud to collaborate with EverZom , a biotech company pioneering extracellular vesicle-based therapies. EverZom has successfully developed an innovation platform protected by several patents, covering the entire technological value chain: cell s
Gameto raises $44M Series C, advances Fertilo to Phase 3 | Gameto posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to … rial using induced pluripotent stem cells (iPSCs) since Shinya Yamanaka’s Nobel Prize in 2012, with potential to be the first ever approved iPSC product in any therapeutic area, and it’s happening in women’s health. Conducted across 20 clinical trial sites in the U.S., this trial will rigorously evaluate Fertilo’s safety and efficacy, bringing more evidence-based, cutting-edge science safely and effectively to patients. 2️⃣ Expanding and strengthening our pipeline Following o … Following our $10 million Advanced Research Projects Agency for Health (ARPA-H) award for our menopause program as part of the White House Initiative on Women’s Health Research, we’re now advancing our implant and vaginal ring for primary ovarian insufficiency (POI) and menopause. Our goal is to bring the vaginal ring to the clinic in the near future and address broader women’s health needs beyond fertility. 3️⃣ Validating investor confidence in women’s and family health This … l Grand Est, the European Innovation Council and SMEs Executive Agency (EISMEA) Fund, SORBONNE VENTURE by AUDACIA, Aloe Private Equity, Paris Business Angels, Capital Cell and several family offices. This major milestone will enable EVerZom to enter the clinical stage in 2026 with EVerGel™, our first therapeutic candidate developed for Crohn’s perianal fistula, a highly debilitating condition affecting thousands of patients worldwide. The funds will also accelerate the indust … Grand Est , the European Innovation Council and SMEs Executive Agency (EISMEA) Fund, SORBONNE VENTURE by AUDACIA , Aloe Private Equity , Paris Business Angels , Capital Cell and several family offices. This major milestone will enable EVerZom to enter the clinical stage in 2026 with EVerGel™, our first therapeutic candidate developed for Crohn’s
News - MabDesign About About Board of Directors Experts Council Our Staff Contact us Network The biotherapies sector Member Directory Membership Benefits Become a member Become a Member (Online Payment) Become a Member (Offsite Payment) Services Scientific and business intelligence analysis Innovation funding Scientific and business studies Lead generation Intelligence monitoring Training Presentation INTRA Courses INTER Courses Partners Trainers Information Events Agenda Our international Events MabDesign Partnering Day ICGT Congress Bioproduction Forum AIS Congress Bioproduction Congress I4I
Exclusive license agreement secured with Erganeo for EVerGel, EVerZom's first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search N … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Exclusive license agreement secured with Erganeo for EVerGel, EVerZom’s first drug candidate, a breakthrough treatment for fistulas and fibrosis of the digestive tract. March 5, 2024 | 6 min read Twitter LinkedIn Facebook Email Print EVerZom has announced the signature of a second exclusive license agreement with Ergane … ab innovation contest and the EIC Accelerator program. EVerZom's first clinical application focuses on digestive tissue regeneration using naive exosomes derived from stem cells encapsulated in a gel called EVerGel ™. EVerGel's lead indication is the healing of complex ano-perianal fistulas induced by Crohn's disease. In addition, EVerZom has identified several other indications in its pipeline, all of which have demonstrated proof of concept in vivo. These include stenosis, … en research and industry, in the interests of societal progress. To do this, we fund and support the next generation of French researcher-entrepreneurs, helping them to achieve success and international recognition. As a member of the SATT network, Erganeo is laying the foundations for a desirable future in the Paris Region ecosystem, a breeding ground for innovation with 20,000 researchers in over 350 cutting-edge research laboratories. Since its creation, Erganeo has invest … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
EVerZom raises €10M for exosome-based therapies | Rahul Raj posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked … ng. The round was led by Capital Grand Est , @European Innovation Council (EIC) Fund, SORBONNE VENTURE by AUDACIA , Aloe Private Equity, Paris Business Angels, Capital Cell, and several family offices. This funding will support: 🔹 The launch of EVerGel’s first clinical trial in 2026 (for Crohn’s complex perianal fistulas) 🔹 Expansion into new indications including hepatology and dermatology 🔹 Further scaling and industrialization of its GMP-compliant exosome bioproduction … ases vs 12.5% in controls. The round was backed by Capital Grand Est , the @EIC Fund, SORBONNE VENTURE by Audacia, Aloe Private Equity , and Paris Business Angels . Virginie MIATH , Investment Director at Capital Grand Est , called EVerZom “the new generation of European biotechs.” https://lnkd.in/gGU8HpSU EVerZom Secures €10M to Advance Groundbreaking Exosome-Based Biotherapies for Inflammatory Diseases - THE TIMES MAGAZINE https://thetimesmag.com 5 Like Comment Share Copy L … ction. Their oversubscribed seed round, led by UK Innovation & Science Seed Fund [UKI2S] and joined by Eos Advisory, o2h Ventures , Hex Two, LongRiver Investments , Cambridge Enterprise Ventures and Parkwalk Advisors , marks a major step forward in advancing this groundbreaking science. With world-class expertise from the University of Cambridge and beyond, CamGene is developing a new generation of therapeutics that could benefit millions globally. Congratulations to Arpa
Metabolic Collaboration and Licensing Agreements Benchmark Report 2026: Access Structured Analysis of 639 - Financial Terms, Upfronts, Stage, Asset Type, Milestones, and Royalties Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management B … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,529.89 +68.26 +0.65% GBP/USD 1.3207 +0.0043 +0.32% GBP/EUR 1.1599 +0.0009 +0.08% FTSE 250 23,161.41 +59.89 +0.26% AIM 771.92 -5.45 -0.70% GOLD FUTURES 4,039.90 +31.10 +0.78% ADVERTIS … im Eracal Therapeutics Eton Pharmaceuticals European Union Regional Development Fund European Wellness Biomedical Group EVA Pharma EverlyWell Eversana EVerZom Evgen Pharma Evidation Health Evo Foods EVOQ Therapeutics Evotec Evozyne Ewopharma ExCEEd Orphan Fermbox Bio First Wave Bio FitBit Flagship Biosciences G3 Therapeutics G42 Healthcare Gain Therapeutics Galapagos Galectin Therapeutics Galmed Pharmaceuticals Gan & Lee Gannex Pharma Gastrologix GATC Health GC Pharma GE Heal
EVerZom enters research and licensing agreement with GENFIT - Pharmafile About us Advertise Contact Follow Follow Follow home News News Press releases Features Features Thought Leadership White papers Case studies Appointments Business Sectors Business Services Manufacturing and Production Medical Communications Research and Development Sales and Marketing Webinars The Pharmafile Brief January/February 2026 – The Pharmafile Brief December 2025 – The Pharmafile Brief November 2025 – The Pharmafile Brief October 2025 – The Pharmafile Brief September 2025 – The Pharmafile Brief August 2025 – The
%PDF-1.7 %���� 4 0 obj >] /Length 231615 >> stream x��uT\]�/��@��!���NA >���{Hzy!!���CC��qA� ��=TTĻ���T�{����U_��9��~�O����Xm���)��!)9#3 + �����ȳ��2�r� ��Z�:�z�f�o,,���]\��= ���/em��j'�&N��$ |����T��f�5��oi����U�9 � r�5�}�.l�m2R ,�!PNqڻ�j���R��3QPN܃?�$p��eG��I�@�kɹ��RdA���SE0y�͇L� ?�1��^ �x��"�L)�t�~:$ü�X9C��M_8�� ����6u��9ʾ>+Ir��] 9~>���*�sJȳg�Ĺg��>����t��=OM�$z_Fz��9w>{���N [�$���kh�����'L�0�8Zj�o��h��O��xB)k7^zS1o�ǔ�� ��SR|&s?���6�e�$N8K����u��0�za� ����������O�K��� �{����?��d��*��kQiDA|��GePcp�s3s��.#�piB��(�;�ѯ�f�b … x�SL�\[��� ��ﴌܗ�b �9"�{!��\ Ӥ�9"�A�&�I����V��gE� )rt � �Df�o��f�Y�|kpEޏrFp"��Yq�>�;����?�{b�ޅ�6,�J��-�I8{T�K!g� 'u:���#c�.��Y����Y��Փe�j ,~6��g�oc��N���v��v �I�ei�r����$�`+���Q>�'��������O��7U��� � ݁���7� �ņ�O ����D̔�����_�߾��ѻl���4u?A�r��Y��p�s��� ��������&=�_5-Ё������ �Q�2-p'M�L}����y������*Jաh:r`��٢џz����j$骚[�SB� �ٽ�@O�E���R�eѴj�� �Ebv XY[(8e�4`���R9��$�f �^f��ՖZ��2��龚|>�C��|��_����*��?���N��II�� -�Ph���\kO.�x?6+��DB
We are proud to announce that ArThec S.A. has officially joined Klaster LifeScience Krakow! As a biotechnology company focused on tissue engineering and regenerative therapies for cartilage repair,… | ArThec S.A. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at an … Explore cutting-edge research with rigorous peer review and rapid publication. Submit your manuscript: https://lnkd.in/deZJNi23 Join us in advancing science and technology through open-access knowledge. #ScifinitiPublishing #PharmaceuticalsAndNanotech #OpenAccess #Nanotechnology #PharmaceuticalResearch #ScientificPublishing #InnovationInScience Scifiniti Publishing 3,887 followers 8mo Scifiniti Publishing is proud to announce the launch of its newest open-access journal — Ph … ovation across these fast-evolving disciplines. Visit: https://lnkd.in/gEVZQ_cA Submit your manuscript: https://lnkd.in/dwWuvBmn Join us in celebrating this milestone as we continue to expand Scifiniti’s mission — connecting science, technology, and society through open-access knowledge. -- Ahmed ElGendy , Amal Amin , Bahaa Elgendy , Elbadawy Kamoun , Fuwu Z., Hui Gao, Khaled Galal, Ph.D. , Mohamed A. El-Mokhtar, Noura G. Eissa , rabab el sherif #ScifinitiPublishing #Pharmace … ovation across these fast-evolving disciplines. Visit: https://lnkd.in/gEVZQ_cA Submit your manuscript: https://lnkd.in/dwWuvBmn Join us in celebrating this milestone as we continue to expand Scifiniti’s mission — connecting science, technology, and society through open-access knowledge. -- Ahmed ElGendy , Amal Amin , Bahaa Elgendy , Elbadawy Kamoun , Fuwu Z., Hui Gao, Khaled Galal, Ph.D. , Mohamed A. El-Mokhtar, Noura G. Eissa , rabab el sherif #ScifinitiPublishing #Pharmace … s post Here are the finalists in the Start-ups category of the Swiss Technology Award 2025 - three teams turning cutting-edge science into real-world impact: AlveoliX is a Swiss biotech company developing organ-on-chip models to replicate any organ in vitro, including its mechanical forces, enabling more accurate, ethical, and cost-effective drug
EVerZom and GENFIT team up on exosome therapy for severe liver disease | Biotechnology | The Pharmaletter Thursday 25 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rar
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Our history - Everzom 🔬 Skip to main content About us Who we are Our history Exosomes Exosomes : nano-messengers in intercellular communication Naive exosomes : overcoming cell therapy limitations Engineered exosomes : overcoming delivery limitations Innovation platform Therapeutic programs Scientific Resources Partnering Our history From the start… The company EVerZom has been officially created in September 2019 but it all started in July 2017 with the filing of the first EverZom patent by Université de Paris/CNRS and Genethon. Jeanne & Nicolas met and started to work full ti … ch, a subsidiary of Universal Medica Group, organized its 2018 Innovation Grand Prize. The Jury was composed of experts from the public and private sectors, representing the pharmaceutical industry, biotechnology and medical device companies, value-adding structures, institutes, investment firms and intellectual property attorneys. Winner of the Business Plan Competition TERMIS Congress MAY 2019 – The Tissue Engineering and Regenerative Medicine International Society (T
%PDF-1.7 %���� 9306 0 obj > endobj 9399 0 obj >/Filter/FlateDecode/ID[ ]/Index[9306 139]/Info 9305 0 R/Length 273/Prev 23317503/Root 9307 0 R/Size 9445/Type/XRef/W[1 3 1]>>stream h�bbd```b`�u� �A$�F��"c�Ȉ ��f��!�@"�S@�:K��$� f�n�" ��lX�NɴL>���;�+D2~�_��U�� 0�#���߂�?`l�$هH$X ��I�"��&o����I�]$��`2 �%�������=�� 2��l 7�"���Iap�e"l���"��0̉�:&!"�Xf������D��� $$�A�u%`v X}��X$+Od`bdP� P~D���� `��K0 endstream endobj startxref 0 %%EOF 9444 0 obj >stream h��Yy|E�~��g�g&���"�$tB Ba� !bT���uP�p�!��YEd�AQ�e1�(��ZAͺq 5^�dQ�o�/���[����9� `�]w�~���z … E56A5D71F63633B xmp.did:71B754480C206811B69993FA99419123 default converted from application/x-indesign to application/pdf Adobe InDesign CS6 (Macintosh) / 2017-12-21T19:59:17+02:00 application/pdf Adobe PDF Library 10.0.1 False endstream endobj 9391 0 obj >stream H��Wko�H�������K��vUM��n�������E�c3��c��m @bHb�d;D�vݺU�s >�w��TeҸ��Q*�-9���п��f�(L���-'_0�387�8Q�X�$̰yZض������! b�������q��'���/N�O���,� Ӽ�����N�\��s����E;��2y���҉��Q̲ ���Y^���j����x��>�'a�{ … (j�"��%�g��h��ibN�St��34q����"@t�F��f�ؗ���Έb�D� �x��U��j)��%_5�.�� S�� c�rFp���R)J�$� �s=F8��J�dJ�F�xa�u�*\Z�h'w]Q��'� Vl��y���ȷ�Vz+,Ԭ� �i̳ڏ���mq�,�'[ǮC|I��}�IN�XH[e v��k���yE��R1�|%�SE�O@�8�DP'� ��s����6)�o|��_!�'�h�L��d� [ ƍZӥ�u{�w��u� �m�f�WԺ�v�P|{�����(�?xg�u�7�s�x�QKmk1�K���Z�B ��8w��S:�춭�+ ��f�l���&��(_^z������"�so�F}$��MR��z�9K�&�T#pc��4�������Bhg�G� �K��,�;�EP�%]F�Vָ� a;�8���2�E�^4�E& )X��z�&�Ba ��SFkQH�?��z�7��$�8���ڐv�a�}�n0K … A��džT�}���� R��J�n�zy[�Cr �8ӇP H](��Q ̓�z�8�\�>�����S�ʻB$tw~��DŽ�=evQ�4�ͅRfP�J� *�~L�ȫmH�H�#�=���Dx�!\� �)f��f�kE��܋2JM;=�d�t~R!oZf����Nw��+�rL�l �B�k69ewK�GI�����۾���B�j~��7>X6���Z�%�̝4�W�)�b�NM9��}:r��o��:dF�]Y�*Y)�\lkC����{ ,N����E�f|�dI��W b�L���r#M@�c��$�X�L0f���� �l&�:�nF���� i�Ћ�oE�����y���TO�d� �f^�n��58J���@w�T���B�Ɋ��� ��k���&f��_s�(x��P�rV��^2�x�y��I�1-vnF~-�Eeؤ�Nkd$�F��Ү 8�=�/��� o�?b0��l�� $�����ȇ� N�yM��a�j" … ڠ�'ML0�� �Cqm��� ���϶��m[ ]>z.�w�D� vY=�4����f��j|� 6��y� �y��� t� � �Ey��վRfP��0�r�WA/_��� ���.a❝� :���E� �?����]R 6Vʿ��$ -� ��Զ�Z@�d� ���f��f�Zv�Z}湢�G�;�= `|+�� �����3�s)��g�7 )� � ��?�[�gd�(�C ��~8ˁ8�O�2��翸9W�s/�_��� .���� X�Q!�r4��r{��|"$X��|" �s�� e����w�l +��|�� M��l���ۼ�/�?d)_�H\ua�o"~��*J+ɰB�?K
GENFIT Enters Research Collaboration with EVerZom to --> Accessibility: Skip TopNav English French GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF November 10, 2025 01:45 ET | Source: GENFIT S.A. GENFIT S.A. EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative therapies Pending successful in vivo proof-of-concept results, GENFIT has an exclusive option to take a license to drive EViv into clinical development Under this researc … ions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr
Le Pitch : EVerZom veut traiter la maladie de Crohn - 25/06 Menu Radio Direct Arrêts de réacteurs Prix du pétrole Entreprises International Économie et social Défense Tech Bourse Patrimoine Immobilier Emploi Conso Crypto Auto Luxe Espace pro BFM En ce moment Précédent Suivant Arrêts de réacteurs Prix du pétrole La canicule en France Le Slip Français en Bourse Hausse de la dette Guerre en Iran Tous les directs BFM Business Direct TV Direct Radio Tous les formats Émissions Podcasts Vidéos Newsletters Évènements Toutes les rubriques Économie et Social Toute l'actu Économie et Social France Mo
Le Pitch : EVerZom veut traiter la maladie de Crohn - 25/06 Menu Radio Direct Arrêts de réacteurs Prix du pétrole Entreprises International Économie et social Défense Tech Bourse Patrimoine Immobilier Emploi Conso Crypto Auto Luxe Espace pro BFM En ce moment Précédent Suivant Arrêts de réacteurs Prix du pétrole La canicule en France Le Slip Français en Bourse Hausse de la dette Guerre en Iran Tous les directs BFM Business Direct TV Direct Radio Tous les formats Émissions Podcasts Vidéos Newsletters Évènements Toutes les rubriques Économie et Social Toute l'actu Économie et Social France Mo
Le Pitch : EVerZom veut traiter la maladie de Crohn - 25/06 Menu Radio Direct Projet de loi logement KNDS en Bourse Entreprises International Économie et social Défense Tech Bourse Patrimoine Immobilier Emploi Conso Crypto Auto Luxe Espace pro BFM En ce moment Précédent Suivant Projet de loi logement KNDS en Bourse La canicule en France Sanctions contre l'Iran Soldes d'été L'épargne des Français Tous les directs BFM Business Direct TV Direct Radio Tous les formats Émissions Podcasts Vidéos Newsletters Évènements Toutes les rubriques Économie et Social Toute l'actu Économie et S … 39;émission Good Morning Business, ce mercredi 14 juin. Ils ont parlé d'une application de mise en relation entre restaurateurs et extras, sur BFM Business. Retrouvez l'émission du lundi au vendredi et réécoutez la en podcast. Morning Briefing : Le point sur les marchés - 24/06 Publié hier Durée : 2:12 2:12 Tous les matins, Étienne Bracq revient sur les performances des principaux marchés boursiers et les tendances du moment dans Morning Briefing, dans l'émission
EVerZom ambitionne de traiter la maladie de Crohn Menu Radio Direct Arrêts de réacteurs Prix du pétrole Entreprises International Économie et social Défense Tech Bourse Patrimoine Immobilier Emploi Conso Crypto Auto Luxe Espace pro BFM En ce moment Précédent Suivant Arrêts de réacteurs Prix du pétrole La canicule en France Le Slip Français en Bourse Hausse de la dette Guerre en Iran Tous les directs BFM Business Direct TV Direct Radio Tous les formats Émissions Podcasts Vidéos Newsletters Évènements Toutes les rubriques Économie et Social Toute l'actu Économie et Social France Monde Union
The Therapeutic Potential Of Exosomes Get more Cell & Gene insight with our FREE newsletter sign me up Log In or Subscribe Explore CGT Production Vectors Cell Therapy Manufacturing Gene Therapy Manufacturing Formulation Fill-Finish Cold Chain Management Quality Control & Assurance Find Suppliers Clinical Trial Services Manufacturing Regulatory Supply Chain Outsourcing Translational Research Watch Now STREAM Video Channel Cell & Gene Live Cell & Gene: The Podcast Cell & Gene Tech Expo Our Communities Advancing RNA Bioprocess Online Clinical Leader Clinical Supply Leader Drug
Jeanne Volatron, CEO d'EVerZom - Le Déclic #Deeptech Saison 2 | Podcast on Spotify
Jeanne Volatron, CEO d'EVerZom | Le Déclic #Deeptech Saison 2 | Ausha Le Déclic #Deeptech Saison 2 Le Déclic #Deeptech Saison 2 Jeanne Volatron, CEO d'EVerZom Jeanne Volatron, CEO d'EVerZom 20min | 09/30/2021 Play Le Déclic #Deeptech Saison 2 Le Déclic #Deeptech Saison 2 Jeanne Volatron, CEO d'EVerZom Jeanne Volatron, CEO d'EVerZom 20min | 09/30/2021 Play Description Dans le bain. Jeanne Volatron, fille de chercheurs, a évolué dans l’univers scientifique depuis le plus jeune âge. Mentor. C’est à l’occasion d’un séminaire lors de son doctorat que le déclic à eu lieu et
EVerZom Secures €10M to Advance Regenerative Medicine Therapies LATEST By Country Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta Netherland Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden Switzerland United Kingdom New List Your Startup Join Now Login Startup News Startup Stories Startup Insight By Country Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Malta Netherland Norway Poland … nding round was led by Capital Grand Est, the European Innovation Council (EIC) Fund, Sorbonne Venture by Audacia, and Aloe Private Equity, with participation from Paris Business Angels, the Capital Cell platform, and multiple family offices. The company plans to use the funding to start its first clinical trial of EVerGel in 2026, explore new therapeutic applications of its exosomes in hepatology and dermatology, and further scale and industrialize its GMP-compliant exosome
EVerZom Raises €1.1M to Industrialize Exosome Biomanufacturing Platform genprowebdirectory End Meta Pixel Code --> Facebook Linkedin RSS Twitter Youtube GEN Edge Featured News Multimedia Content News Insights Topics Artificial Intelligence Bioprocessing Cancer Drug Discovery Genome Editing Infectious Diseases OMICs Translational Medicine Magazine Browse Issues Subscribe Multimedia Summits Webinars GEN Live Learning Labs Podcasts Videos Resources A-Lists eBooks/Perspectives Tutorials Peer-Reviewed Journals GEN Biotechnology Re:Gen Open New Products Subscribe Get GEN Magazine Get GEN eNewsletter … robust quality and reproducibility, says Volatron. The company’s approach is to apply turbulence stimulation on cells to trigger massive exosome release. This method enables the production of ten times more exosome ten times more rapidly than classical methods, claims Volatron. The technology is being developed and already implemented in GMP certified systems, simplifying the clinical transfer, she notes. “We are delighted with this financing opportunity, which will ena
Jeanne Volatron, CEO d'EVerZom – Le Déclic #Deeptech Saison 2 – Apple Podcasts Tìm Kiếm Trang chủ Khám phá Top bảng xếp hạng Tìm Kiếm 30 tháng 9, 2021 21 phút Jeanne Volatron, CEO d'EVerZom Le Déclic #Deeptech Saison 2 Phát Dans le bain. Jeanne Volatron, fille de chercheurs, a évolué dans l’univers scientifique depuis le plus jeune âge. Mentor. C’est à l’occasion d’un séminaire lors de son doctorat que le déclic à eu lieu et qu’elle a rencontré LA personne déterminante. Pour bientôt. Fondée en 2019, sa société EVerZom, qui innove dans la médecine régénérative, est en passe de lancer ses essais
#biotech #healthtech #regenerativemedicine #impactinvesting #exosomes | EVerZom LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User A … ng. The round was led by Capital Grand Est , @European Innovation Council (EIC) Fund, SORBONNE VENTURE by AUDACIA , Aloe Private Equity, Paris Business Angels, Capital Cell, and several family offices. This funding will support: 🔹 The launch of EVerGel’s first clinical trial in 2026 (for Crohn’s complex perianal fistulas) 🔹 Expansion into new indications including hepatology and dermatology 🔹 Further scaling and industrialization of its GMP-compliant exosome bioproduction … ristian and his team, with support from visionary investors at Novartis Venture Fund and OrbiMed realized that this wasn’t just about #fibrosis . The same approach could unlock treatments for #oncology , monogenic blood disorders, and even autoimmune diseases. The insight? 👉 Transition from a product to a platform. 👉 Build something that could serve multiple therapeutic frontiers, not just one. But with big opportunities come big debates. Investors pushed for oncology the f
A Game-Changing Moment for MedTech. | Iain McCulley (CMgr FCMI) LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Priva … new private & public based ownership group, along with Thiel Bio , Founders Fund , and other #investors , following a $2.25 billion #acquisition of a majority stake in August 2025. HistoSonics plans to accelerate development of new #clinical indications, expanding beyond #liver tumors to #kidney , #pancreas , and #prostate , aiming to broaden histotripsy applications for both benign and malignant conditions. The company will also use funds to strengthen operational capaci … l Grand Est, the European Innovation Council and SMEs Executive Agency (EISMEA) Fund, SORBONNE VENTURE by AUDACIA, Aloe Private Equity, Paris Business Angels, Capital Cell and several family offices. This major milestone will enable EVerZom to enter the clinical stage in 2026 with EVerGel™, our first therapeutic candidate developed for Crohn’s perianal fistula, a highly debilitating condition affecting thousands of patients worldwide. The funds will also accelerate the indust … ristian and his team, with support from visionary investors at Novartis Venture Fund and OrbiMed realized that this wasn’t just about #fibrosis . The same approach could unlock treatments for #oncology , monogenic blood disorders, and even autoimmune diseases. The insight? 👉 Transition from a product to a platform. 👉 Build something that could serve multiple therapeutic frontiers, not just one. But with big opportunities come big debates. Investors pushed for oncology the f
EVerZom raises $1.3m to industrialise exosome biomanufacturing platform Home Categories Ingredients Analysis Manufacturing Finance Company News Regulatory Drug Delivery Research & Development Sustainability Pharma 5.0 Events Directory Search Close search Subscribe Login Password Password Remember me Forgot password? Close login form Manufacturing Chemist Home Manufacturing EVerZom raises $1.3m to industrialise exosome biomanufacturing platform EVerZom raises $1.3m to industrialise exosome biomanufacturing platform Published: 7-Dec-2020 Manufacturing Pharmaceutical This funding will speed u … continuing its work on the link between the qualification of exosomes and their application potential. EVerZom's ambition is to become the European leader in the bioproduction of exosomes. "We are delighted with this financing opportunity, which will enable us to industrialise our proprietary technology and meet the growing demand of the exosome market. Our ambition is to foster the emergence of new exosome therapeutic strategies and to make them accessible to the largest pos
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Op … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update April 2, 2026 | 28 min read Twitter LinkedIn Facebook Email Print 2025 financial highlights: Cash and cash equivalents totaled €101.1 million as of December 31, 2025 Revenues amounting to €65.4 million for the period ended Decem … D, potentially enabling eligibility for a Priority Review Voucher upon New Drug Application approval. Other developments In 2025, GENFIT contributed to positioning ACLF as a strategic focus within the Forum for Collaborative Research , an independent multi‑stakeholder initiative bringing together regulators, industry leaders, academics, clinicians, scientists and patient groups to help shape and accelerate drug development in areas of high unmet medical need. Financial highli … , 2025. We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the end of 2028, enabling the Company to further develop its R&D pipeline and support general corporate purposes. This is based on current assumptions and programs and does not include exceptional events. This estimation assumes (i) our expectation to receive significant future commercial milestone revenue pursuant to the … T‑015, VS‑02‑HE and EViv; and the Company’s expected cash runway and ability to fund operations beyond the end of 2028, including assumptions regarding future milestones and optional drawdowns under the royalty financing agreement. . The use of certain words, such as "believe", "potential", "expect", “target”, “may”, “will”, "should", "could", "i
%PDF-1.6 %���� 15 0 obj >] /Length 152905 >> stream x���wTS����"��[@P �J�P�R�A�"MPc�=� �*M��QU@Dz���R'���|���13���ޔs�>{?�n�|�|���Ds����2��+W�����]cb��-��-�)%U���ܹ)�j��3��%�-l-�l�0�!�MH�\����(��$h(-&m����y;���������@�@B�@r� �H(H.~������SPRQ�4ႆ�R22Rr2 rr��`�y9�5 5JF�-�'P2,>��O��#|� ~);��K4�o0�� �D��2wd��5�jB��u��&�f���[�;8:9� \������F���z��52!1)9%5- �_P�)*.�����7�mljn��щ�����Ï���OL~��1�����������������#�Hd$��� a\���ANE � �r �kj0*[OF^�0j�z|^��K|R��켆i����v1��������7�������0yd @�Z���%Z��ݓ���r�J�R��c}�C��t��:(��|@�B>p�pS���ۥQ���IԾ� .@ZI
Lonza Group - Today, we announced a collaboration with... Facebook Log In Lonza Group's Post Lonza Group Verified account September 23, 2025 · Shared with Public Today, we announced a collaboration with RION to provide cGMP manufacturing and technical support for commercial scale production of its Purified Exosome Product™ (PEP™) drug substance for late phase clinical supply and beyond. PEP™ is an exosome-based therapeutic platform candidate with immunomodulatory, anti-inflammatory and tissue regenerative properties. Stabilized regenerative exosomes promote tissue repair and can be admini
EVerZom signed a licensing agreement with Université de Paris covering an innovative extracellular vesicle bioproduction process - Exosome RNA --> Don't Miss ’Footprint of Death’ gives new clues to cell life Positive CAR-exosome in vitro tumour killing demonstrated in ovarian cancer cells UC San Diego Researchers Receive ARPA-H Award to Make Birth Safer iMSC-derived extracellular vesicles may offer a new approach for osteoarthritis treatment Maternal weight may influence microbiota signalling in amniotic fluid SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alz … ted in ovarian cancer cells 6 hours ago UC San Diego Researchers Receive ARPA-H Award to Make Birth Safer 1 day ago iMSC-derived extracellular vesicles may offer a new approach for osteoarthritis treatment 1 day ago Maternal weight may influence microbiota signalling in amniotic fluid 2 days ago SECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer’s disease 2 days ago Social Networking Pages Exosome RNA 3,188 Followers 123 Fans © Copyrigh
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF Skip to main content Euronext websites Euronext.com Connect - client portal EN en fr nb nl pt de it Toggle navigation Toggle Page Menu --> Search Search Search Search Search My profile My Subscriptions Watchlists Quote alerts Create account Sign in Markets close menu Amsterdam Stocks Indices ETFs Bonds Funds Structured products Derivatives Brussels Stocks Indices ETFs Bonds Structured Products Derivatives Dublin Stocks Indices ETFs Bonds Irish Government Bonds Funds Daily Official List (D … ions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr
Edition 2024 - Innovative Therapies Days My ticket FAQ Contact us Program Exhibitors Call for abstracts History Committees Partners October 8th, 09th, 2026 Kursaal - Besançon Become an exhibitor Get tickets menu#toggle" > menu#toggle"> Program Exhibitors Call for abstracts History Committees Partners Edition 2024 2 DAYS OF HIGH LEVEL CONFERENCES The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation. WEDNESDAY, OCTOBER 09TH 17:00-21:00 : WELCOME EVENING & POSTER SESSION (BIO INNOVATION)
%PDF-1.7 %���� 1 0 obj >/Metadata 707 0 R/ViewerPreferences 708 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��][s�8�~OU�� �و!�$��\��L���N��j�灱h������\������9/� ��� M� ���r.8����z���כ�?�>�l��f6�����?}_5��o�E�i��� ?o��_�z֬��&o~���~�QNn ^����y������Ȋf���Jd�N�2*&������d��EɋLLr�?\�MY��������������m��, � 1/-9�*:z�O��+2��8�|�y���OL� @3^�:�jUl�O��>�>���o`W�)���o���ǼT}��>�kx���}w��7�;�&��.r S ����4�?qV���E�n �8 2 H1�*�8y�;� �
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
EVerZom | Capital Cell Investment opportunities All opportunities Investor Column 1 Investors Column 2 How does it work? Learn how to join our community Read more Why invest with Capital Cell? Discover the biotechnology revolution Read more Secondary market Connect and negotiate directly with other investors Read more Our portfolio Explore all our investments and success stories Read more Column 3 Invite a friend Read more Risk Warning Read more Due diligence Read more What is Marketpay Read more Frequently Asked Questions Read more Company Column 1 Companies Column 2 Fundraising round in Capi … mits of tissue and organ regeneration in the human body. The potential scope of application is therefore immense: neurodegenerative diseases (notably Alzheimer’s), age-related conditions, and even cosmetics. In total, more than 150 million patients could ultimately benefit from these new therapeutic approaches. EVerGel, the drug candidate for treating Crohn’s disease fistulas, shows very promising results EVerGel, an exosome-based healing gel, targets complex peri … inflammation and the risk of fibrosis, EVerGel stands out for its simple local application and rapid, high-quality monitoring of its effectiveness. Preclinical results are very promising: 87.5% complete healing at 4 weeks in porcine models, compared to 12.5% in the control group. A committed team and significant support EVerZom has 13 employees with complementary backgrounds : medical development, bioproduction, innovation, and business. Founded by Jeanne, Nicolas, and four
%PDF-1.4 %���� 1124 0 obj > endobj xref 1124 79 0000000016 00000 n 0000002517 00000 n 0000002697 00000 n 0000002743 00000 n 0000004388 00000 n 0000004578 00000 n 0000004877 00000 n 0000004992 00000 n 0000005890 00000 n 0000006178 00000 n 0000006463 00000 n 0000006578 00000 n 0000015276 00000 n 0000023974 00000 n 0000024099 00000 n 0000032689 00000 n 0000032804 00000 n 0000039887 00000 n 0000048081 00000 n 0000048431 00000 n 0000048879 00000 n 0000049343 00000 n 0000050027 00000 n 0000050492 00000 n 0000050948 00000 n 0000051538 00000 n 0000052117 00000 n 0000052233 00000 n 0000052346 00000 n 0 … ng /Users/kateandpatrick/Downloads/RE_ Logo for ISEV2022/ISEVShortLogo_2019.png application/pdf 2340x280_ISEV2022_recreated Adobe Illustrator 26.2 (Macintosh) 2022-05-04T12:48:54-04:00 2022-05-04T12:48:55-04:00 2022-05-04T12:48:55-04:00 1 True False 33.661800 5.521295 Inches AvenirNext-DemiBold Avenir Next Demi Bold TrueType 13.0d1e10 False Avenir Next.ttc Montserrat-SemiBold Montserrat SemiBold Open Type Version 7.200;PS 007.200;hotconv 1.0.88;makeotf.lib2.5.64775 False Mont … ng /Users/kateandpatrick/Downloads/RE_ Logo for ISEV2022/ISEVShortLogo_2019.png application/pdf 2340x280_ISEV2022_recreated Adobe Illustrator 26.2 (Macintosh) 2022-05-04T12:48:54-04:00 2022-05-04T12:48:55-04:00 2022-05-04T12:48:55-04:00 1 True False 33.661800 5.521295 Inches AvenirNext-DemiBold Avenir Next Demi Bold TrueType 13.0d1e10 False Avenir Next.ttc Montserrat-SemiBold Montserrat SemiBold Open Type Version 7.200;PS 007.200;hotconv 1.0.88;makeotf.lib2.5.64775 False Mont … ccff65c970f xmp.did:0323302d-98cf-44ee-9d88-98695ac16800 default converted from application/x-indesign to application/pdf Adobe InDesign 17.2 (Macintosh) / 2022-05-20T08:14:13-04:00 application/pdf Adobe PDF Library 16.0.7 False 1260250655 Avenir Next TrueType Collection 1260250655 Linotype AG 0 AvenirNext-DemiBold 8.0 2389000434 Montserrat OpenType - PS 2389000434 -- 0 Montserrat-SemiBold 7.200 3152672518 Acumin Pro OpenType - PS 3152672518 Adobe Systems 0 AcuminPro-Medium 1 … ccff65c970f xmp.did:0323302d-98cf-44ee-9d88-98695ac16800 default converted from application/x-indesign to application/pdf Adobe InDesign 17.2 (Macintosh) / 2022-05-20T08:14:13-04:00 application/pdf Adobe PDF Library 16.0.7 False 1260250655 Avenir Next TrueType Collection 1260250655 Linotype AG 0 AvenirNext-DemiBold 8.0 2389000434 Montserrat OpenT
Exosome Research Market Size, Share and Forecast 2026 to 2035 We collect cookies to enhance your browsing experience. Learn more X Home Report Pharmaceuticals Medical Devices Healthcare IT Consumer Goods & Services Agriculture Semiconductor and Electronics Technology Veterinary Food & Beverages Packaging Chemicals and Materials Biotechnology Energy and Power Automotive and Transportation Pipeline Reports AI and Digital Technologies Consulting Competitive Intelligence Consulting Hub Due Diligence Go-to-Market Strategy KOL Stakeholder Mapping Opportunity Assessment Pipeline Asset Strategy Revenu … eurodegenerative diseases, cardiovascular diseases, and infectious diseases. By application, the market is segmented into biomarkers, vaccine development, tissue regeneration and other applications. By end users, the market is segmented into academic & research institutes, pharmaceutical and biotechnology companies, hospitals & clinical testing laboratories. Based On Product, The Kits & Reagents Segment Is A Major Contributor In The Exosome Research Market The kit
IMCAS - Congresses on Dermatology and Aesthetic & Plastic Surgery Academy Webinars Library Insider magazine Podcasts Report Sponsor Academy Academy Webinars Library Insider magazine Podcasts Report Sponsor Access is restricted to physicians To watch this video, please sign in Sign in Do not have an account yet? Create your IMCAS account Go back Extracellular vesicles for therapeutic use Share Dr. Clement BONAMY PhD - Research France Abstract Dr. Clement BONAMY PhD - Research Extracellular vesicles for therapeutic use (Everzom) Objectives: Extracellular vesicles (EV) have a high potential i … 27 IMCAS Americas 2027 About The IMCAS story Scientific Partners Feedback IMCAS Fund Discover IMCAS Academy Webinars Library Insider magazine Podcasts Follow IMCAS Need assistance? Contact us Read FAQs Privacy policy Legal information © 2026 IMCAS International Master Course on Aging Science. All rights reserved. Accessibility : non-compliant Congresses IMCAS Asia 2026 IMCAS China 2026 IMCAS World 2027 IMCAS Americas 2027 Discover IMCAS Academy Webinars Library Insider magazi … ider magazine Podcasts About The IMCAS story Scientific Partners Feedback IMCAS Fund Need assistance? Contact us Read FAQs Privacy policy Legal information Follow IMCAS © 2026 IMCAS International Master Course on Aging Science. All rights reserved. Accessibility : non-compliant Processing, please wait... Error Please fill out all required fields. Here are the fields that are missing: OK IMCAS Search... Open menu Congresses IMCAS Asia 2026 19 - 21 June 2026 BANGKOK & ONLIN … us FAQ View our most Frequently Asked Questions Contact How can we help? IMCAS Fund Membership Sign in en IMCAS Close menu Congresses Academy Community About Membership IMCAS Asia 2026 19 - 21 June 2026, BANGKOK & ONLINE IMCAS China 2026 27 - 29 August 2026, SHANGHAI IMCAS World 2027 28 - 30 January 2027, PARIS & ONLINE IMCAS Americas 2027 20 - 22 May 2027, SãO PAULO INVEST by IMCAS 2027 January 27th, 2027, PARIS Webinars Live and on-demand access to the latest in aesthetic
Amaury Genovese :: Institute of Developmental and Regenerative Medicine (IDRM) Skip to Main Content - Click Enter Menu About Us About IDRM Director's Welcome The Building People Research Groups De Val Group Gupta Group Holländer Group Kalisch-Smith Group Mommersteeg Group Riley Group Rinaldi Group Roberts Group Sanders Group Simões Group Smart Group Srinivas Group Stathopoulou Group Stone Group Wood Group Research Staff Transition Fellows Support Staff Affiliated Investigators Governance Partner Groups & Centres Research & Facilities Our Research Cardiology Neurology I
2026 Bio Europe Spring Attendee | LSX Europe You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Life Science Fundraising & Investment 7-8 April 2027 - Main days, Lyon, France 6 April 2027 - Pre-day forums (Life Science Companies only) Home home Biotech expan … s (Guangzhou) Ltd. Choose Paris Region Chordia Therapeutics Inc. Chugai Venture Fund, LLC Chugai Venture Fund, LLC CIC bioGUNE Cilcare Cilcare Claris Ventures Claris Ventures Clayton Biotechnologies, Inc. Clinigen Clinigen Clinigen CNS Pharmaceuticals COCOON BIOSCIENCES Cogitars UK Colab Accelbio Colab Accelbio Colab Accelbio Complement Therapeutics Confo Therapeutics Confo Therapeutics Contera Pharma A/S Contera Pharma A/S CONVEYXO CorriXR Therapeutics CorriXR Therapeutics C … t University Ghent University Ghent University Ghent University GIBF Investment Fund GIBF Investment Fund GIP GENOPOLE GlobalData HealthCare GlobalData HealthCare GlobalData HealthCare GlycoNex GlycoTherapeutics GlycoTherapeutics Gnosis SpA Golgi Neurosciences Golgi Neurosciences Gordian Biotechnology Granzer Regulatory Consulting & Services GmbH Great Bay Bio Limited Greater Geneva Bern area GreenPine Pharma Group Co., Ltd. GreenPine Pharma Group Co., Ltd. Grünenthal Gmb … ents Hyloris Developments HyQure BioTech Co., Ltd HYUNDAI PHARM i&i Biotech Fund I SCSp i&i Biotech Fund I SCSp i&i Prague, s.r.o. i&i Prague, s.r.o. Icosagen Cell Factory OÜ Icosagen Cell Factory OÜ iDEL Therapeutics GmbH iDEL Therapeutics GmbH Idevax IDR Ie Sung International IEUM VALUE CREATOR INC. IGA Technology Services Srl IGES Institut Ignota Labs Ikarovec Limited Ikarovec Limited IMK IC Health Intelligence Immunethep ImmunoDesigners Co., Ltd. ImmunoFor
%PDF-1.7 %���� 1 0 obj >/Metadata 901 0 R/ViewerPreferences 902 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 594.96 842.04] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���MO�0��� �� e�� K���[$h�q�8�J��� ��� ���D�f���=ᇻf}S-���MS-o�kX�r{��?�5�U���j�� ���jڭ uu]�`0,�!���!2�N�3@Z�а���b6q4(� Ipm���#�H�Ii�ζ�O�-�~�ΰ +z^��h�Lr �q �|ßq�� jz/ G2H�U��o.�/X.Xs�E��$1�w�_� ��24�7� �Pt�&�Y�J�Φ��$��(b����4I5��oA�HԪK�u�j9�L��"��4g�y�P�Ot�}��RB�����=Ϊp�|f�pi�vz���B�����j}.�N
EVerZom | | The Pharmaletter Thursday 25 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes Cell And Gene Therapy Conferen
EVerZom raises 10 million euros to push exosome therapy into clinic | Pharmaceutical | The Pharmaletter Thursday 25 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare … round attracted support from Capital Grand Est, the European Innovation Council Fund, Sorbonne Venture, Aloe Private Equity, Paris Business Angels, Capital Cell and several family offices. The funds will back a 2026 trial of EVerGel, the company’s lead program for Crohn’s perianal fistula. The disease is a major unmet need following Takeda’s withdrawal of stem cell treatment Alofisel from the EU market in 2024 after a confirmatory trial failed. Preclinical work with EVerGel s
225 Drug Delivery Companies Worldwide | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Drug Delivery 224 Employers in 321 locations Employers working on Drug Delivery work in 81 other areas Displaying 1 - 15 of 81 related areas Show: 15 50 All Therapeutics (13) Medical Devices (10) Nanoparticles (10) Cell and Gene Therapy (9) Exosomes (9) Biologics (8) COVID
EverZom | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas EverZom Website: EverZom Business Area(s) Exosomes Drug Delivery Regenerative Medicine Description EverZom is developing methods for using exosomes to promote gastrointestinal, liver and kidney regeneration. Company Location(s) 45, rue des Saints-Pères 75006 Paris France body Sign up for news Contact
This page is no longer available The page you are looking for has been permanently removed and is no longer available. Go to Homepage Home Explore Plans
47 Exosomes Companies Worldwide | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Exosomes 47 Employers in 50 locations Employers working on Exosomes work in 32 other areas Displaying 1 - 15 of 32 related areas Show: 15 50 All Therapeutics (17) Regenerative Medicine (11) Drug Delivery (9) Stem Cells (7) Cell and Gene Therapy (4) Neurological Disease (4) Cosme
%PDF-1.5 %���� 1132 0 obj > endobj xref 1132 191 0000000016 00000 n 0000006629 00000 n 0000006746 00000 n 0000009441 00000 n 0000010641 00000 n 0000010904 00000 n 0000012245 00000 n 0000013449 00000 n 0000015260 00000 n 0000016581 00000 n 0000016696 00000 n 0000017769 00000 n 0000017886 00000 n 0000017982 00000 n 0000019184 00000 n 0000020525 00000 n 0000022336 00000 n 0000023543 00000 n 0000024667 00000 n 0000025443 00000 n 0000026420 00000 n 0000027242 00000 n 0000027391 00000 n 0000027788 00000 n 0000027827 00000 n 0000028003 00000 n 0000028329 00000 n 0000029507 00000 n 0000030246 00000 n … �� endstream endobj 1224 0 obj > endobj 1225 0 obj > endobj 1226 0 obj >stream application/postscript Print (Daniel Elliott) 2024-04-18T10:07:42+01:00 2024-04-18T10:07:42+01:00 2024-04-18T10:07:42+01:00 Adobe Illustrator 28.4 (Macintosh) xmp.iid:ebfdda4d-7158-4935-b5e1-a7392be9853e xmp.did:e11a2ffb-bea2-4a9a-aab2-7be668b97b6a uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:f477091f-e84f-4961-ad57-7e51b9533c86 xmp.did:f477091f-e84f-4961-ad57-7e51b9533c86 uuid:5D208924 … 019-04-01T13:47:14+01:00 Adobe Illustrator CC 23.0 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:0508f050-4d78-44e5-8a04-3ad022a8782e 2021-07-16T09:05:33+01:00 Adobe Illustrator 25.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:eecd9456-79ce-4589-920a-ca217ecb2b5c 2022-03-09T16:37:51Z Adobe Illustrator 26.0 (Macintosh) / converted from application/postscript to a … 0 2022-04-26T11:40:45+01:00 Adobe Illustrator 26.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:d95e4b86-972c-41d4-8d10-c93cfe4f75c4 2023-03-15T09:27:46Z Adobe Illustrator 27.3 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3d495f76-9b71-4f61-b4b0-4a77d715cff0 2024-03-11T09:31:28Z Adobe Ill … 533c86 2024-03-11T09:32:15Z Adobe Illustrator 28.2 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:e11a2ffb-bea2-4a9a-aab2-7be668b97b6a 2024-04-18T10:07:42+01:00 Adobe Illustrator 28.4 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from appl
Mother cell source - Everzom 🔬 Skip to main content About us Who we are Our history Exosomes Exosomes : nano-messengers in intercellular communication Naive exosomes : overcoming cell therapy limitations Engineered exosomes : overcoming delivery limitations Innovation platform Therapeutic programs Scientific Resources Partnering Mother cell source The selection criteria for the EV cell source can be divided in two categories: i) the extracellular vesicle intrinsic properties, in line with their therapeutic activity, and ii) the cell line characteristics associated to their robustness for
Selection of cell sources for exosome production - Everzom 🔬 Skip to main content About us Who we are Our history Exosomes Exosomes : nano-messengers in intercellular communication Naive exosomes : overcoming cell therapy limitations Engineered exosomes : overcoming delivery limitations Innovation platform Therapeutic programs Scientific Resources Partnering 15 February 2022 3 mins. read Selection of the optimal cell source for extracellular vesicles production in regenerative medicine or drug delivery Scientific resources Extracellular vesicles (EVs) are vesicles secreted by cells from
Therapeutic programs - Everzom 🔬 Skip to main content About us Who we are Our history Exosomes Exosomes : nano-messengers in intercellular communication Naive exosomes : overcoming cell therapy limitations Engineered exosomes : overcoming delivery limitations Innovation platform Therapeutic programs Scientific Resources Partnering EVerZom proprietary therapeutic pipeline Everzom develops its proprietary pipeline of naïve exosomes in regenerative therapies, large market indications with high unmet medical needs Our goal is to unlock the exosome revolution based on our unique innovation pl
EVerZom - Exosome biotech company Skip to main content About us Who we are Our history Exosomes Exosomes : nano-messengers in intercellular communication Naive exosomes : overcoming cell therapy limitations Engineered exosomes : overcoming delivery limitations Innovation platform Therapeutic programs Scientific Resources Partnering Exosome biotech company The most promising exosome therapeutics ever for digestive tissue healing and organ regeneration. More info element --> A key asset to the future health of an ageing population Extracellular vesicles (EVs) or exosomes are subcellular ent
At the origin of EVerZom : when physics and fluid mechanics meets medicine and biology. On one hand, the daily challenges faced by physicians. A persistent unmet medical need: complex perianal… | Nicolas Rousseau LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at an … us gallus domesticus. This study provides valuable insights into the biomedical application of nanomaterials for wound care and regenerative medicine. Grateful to my co-authors and mentors for their contributions. Keywords: Mn₃O₄ nanoparticles | PEG | PEI | Wound healing | Nanomedicine 3 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Olivia Dyer 8mo Report this post I am super excited to announce that my recent research: “Ex vivo robotic measure … the nervous system at the organism, cellular, and molecular levels. The future application perspectives of THz technologies in neuroscience are also highlighted and proposed. https://lnkd.in/e-ZKNVFd Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in EPFL AI Center 18,702 followers 8mo Report this post The EPFL AI Center and AITHYRA Research Institute for Biomedical Artificial Intelligence have launched a new research collaboration to advance cross … the Frontiers Ahead, Professor Nicholas Peppas, recipient of the 2025 Kabiller Prize in Nanoscience and Nanomedicine, reflects on what this day represents for the field and for scientists everywhere. Watch below and explore the full conversation at iinano.org/podcast #NationalNanoDay #Nanotechnology #Nanoscience #IIN #NorthwesternUniversity …more 19 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 15,477 followers 186 Posts View Profile
What Is The Therapeutic Potential Of Exosomes Get more Cell & Gene insight with our FREE newsletter sign me up Log In or Subscribe Explore CGT Production Vectors Cell Therapy Manufacturing Gene Therapy Manufacturing Formulation Fill-Finish Cold Chain Management Quality Control & Assurance Find Suppliers Clinical Trial Services Manufacturing Regulatory Supply Chain Outsourcing Translational Research Watch Now STREAM Video Channel Cell & Gene Live Cell & Gene: The Podcast Cell & Gene Tech Expo Our Communities Advancing RNA Bioprocess Online Clinical Leader Clinical Supply Lea
Exosomes : EVerZom lève 10 M€ pour commencer la phase clinique de son candidat médicament | Nicolas Rousseau | 45 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … Grand Est , the European Innovation Council and SMEs Executive Agency (EISMEA) Fund, SORBONNE VENTURE by AUDACIA , Aloe Private Equity , Paris Business Angels , Capital Cell and several family offices. This major milestone will enable EVerZom to enter the clinical stage in 2026 with EVerGel™, our first therapeutic candidate developed for Crohn’s perianal fistula, a highly debilitating condition affecting thousands of patients worldwide. The funds will also accelerate the ind … l Grand Est, the European Innovation Council and SMEs Executive Agency (EISMEA) Fund, SORBONNE VENTURE by AUDACIA, Aloe Private Equity, Paris Business Angels, Capital Cell and several family offices. This major milestone will enable EVerZom to enter the clinical stage in 2026 with EVerGel™, our first therapeutic candidate developed for Crohn’s perianal fistula, a highly debilitating condition affecting thousands of patients worldwide. The funds will also accelerate the indust … ng led by its new ownership group, with participation from Thiel Bio , Founders Fund , K5 Global , Bezos Expeditions, and Wellington Management . The round values the Plymouth , MN medtech company at ~$3B, following the majority stake acquired in August 2025 (~$2.25B). What the funding supports: Commercial scale-up of the Edison Histotripsy System (FDA de novo clearance, Oct 2023). Expansion from >50 U.S. centers and >2,000 patients treated to additional sites (~50 more … Frazier Life Sciences , Andera Partners , Deep Track Capital, Bayern Kapital , Fund+, OCCIDENT , Seventure Partners , and HTGF | High-Tech Gründerfonds — also joined the round. 𝗥𝗘𝗔𝗗 𝗧𝗛𝗘 𝗗𝗘𝗧𝗔𝗜𝗟𝗦 👉 https://lnkd.in/dsXBq_zi Dr. Anil Jagtap Adriane Krahe Bjoern Hock Günter Fingerle-Rowson Stella Paffenholz, PhD Inês Vasconcelos Bettin
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
#regenerativemedicine #biotech #exosomes #healthcareinnovation #investment | EVerZom LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s U … Natacha Coppieters , Christina Nguyen , Quentin Graillet ! Link to download the Application Note in the comment! #Spheroid #HighThroughput #DropletMicrofluidics #iPSC #StemCell #CellTherapy #Biomanufacturing #Innovation 55 2 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Biomed | NXTGEN Hightech 843 followers 8mo Edited Report this post Redefining Healthcare Through Nanoscale Precision | At the NXTGEN Hightech Conference tomorrow, the B
Discover the EverZom team - Everzom 🔬 Skip to main content About us Who we are Our history Exosomes Exosomes : nano-messengers in intercellular communication Naive exosomes : overcoming cell therapy limitations Engineered exosomes : overcoming delivery limitations Innovation platform Therapeutic programs Scientific Resources Partnering EVerZom Team We are driven by our shared belief in the therapeutic potential of exosomes . Our mission is to work towards the democratization of exosome-based therapies: to bring affordable and easily accessible therapeutics to patients with unmet medical
ISCT 2026: Exosomes Scientific Signature Series Event - ISCT 2026 Dublin ISCT | Connecting Science to Medicine Skip to main content (Press Enter). Login Skip auxiliary navigation (Press Enter). ISCT Journal Media Contact Us Subscribe to ISCT 2027 Skip main navigation (Press Enter). Toggle navigation Home Accreditation Program Program at a Glance Translational Pathway Program Roundtable Program Lab Practices Essentials Track Program Schedule Corporate Program Speaker Line Up Keynote Speaker Training Events Thought Leadership Events Networking Events Gala 5K Run Abstracts Submission … nts Gala 5K Run Abstracts Submission Information Presenter Information Abstract Award Winners Sponsors & Partners Sponsor & Exhibit Partners Innovation Zone Resources ISCT 2026 FAQ Social Toolkit Partnering ISCT 2026: Exosomes Scientific Signature Series Event The Exosomes Scientific Signature Series brings together global experts to explore the evolving science, translation, and clinical application of extracellular vesicles (EVs) and the broader secretome . Sessions will ex
#isev2022 | Nicolas Rousseau LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Ski
OmniSpirant and EVerZom Team up to Develop a New Gene Therapy Treatment for Lung Cancer With Extracellular Vesicles - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search OmniSpirant and EVerZom Team up to Develop a New Gene Therapy Treatment for Lung Cancer With Extracellular Vesicles December 6, 2022 | 2 min read Twitter LinkedIn Facebook Email Print OmniSpirant Limited and EVerZom are delighted to announce the launch of INSPIRE, a €12.8 million lung cancer project funded by Horizon Eu … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Winner of the European EIC Accelerator Program, EVerZom Accelerates the Industrialization of Its Exosome Bioproduction Platform for Regenerative Medicine - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Winner of the European EIC Accelerator Program, EVerZom Accelerates the Industrialization of Its Exosome Bioproduction Platform for Regenerative Medicine November 18, 2021 | 2 min read Twitter LinkedIn Facebook Email Print EVerZom, a biopharmaceutical company specialized in the biomanufacturing of extracellular vesicles … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Winner of the “Biotherapies and Bioproduction” call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology June 17, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Winner of the “Biotherapies and Bioproductio … ine strategic orientations and flagship actions. Project leaders are invited to submit their applications through open, rigorous, and selective procedures to benefit from State support. ✔ Is managed by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the French Environment and Energy Management Agency (ADEME), the National Research Agency (ANR), Bpifrance, and the Banque des Territoires. More information: france2030.gouv.fr | @SGPI_ave … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
EVerZom: Therapeutic Ambition in Exosome Biotherapies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases Al … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search EVerZom: Therapeutic Ambition in Exosome Biotherapies December 13, 2023 | 4 min read Twitter LinkedIn Facebook Email Print EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform. EVerZom: Th … pipeline of exosome-based biotherapies. EVerZom aims to accelerate the clinical application of this novel therapeutic approach in a wide range of indications where medical need remains critical. Its most advanced drug candidate targets digestive tissue healing. Paris, December 13, 2023 - EverZom , a CNRS/University Paris Cité spin-off specializing in exosomes, today unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platfor … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Ce … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF November 10, 2025 | 7 min read Twitter LinkedIn Facebook Email Print EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel … ions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin